Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: A tissue microarray-based study

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 5, 2010, Pages 433-441

  Nassar, Aziza ^a   Radhakrishnan, Anuradha ^b   Cabrero, Isabella A ^e   Cotsonis, George A ^c   Cohen, Cynthia ^d  

^a MAYO CLINIC   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

breast cancer; estrogen receptor; immunohistochemistry; tissue microarray; tumor heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER; UVOMORULIN;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; GENETIC HETEROGENEITY; HUMAN; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; MEDULLARY CARCINOMA; MICROSCOPY; MUCINOUS CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; TISSUE MICROARRAY; TISSUE SECTION;

ANTIBODIES, MONOCLONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA; DIAGNOSTIC ERRORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, HUMAN; MICROARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957578065     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181dddb20     Document Type: Article

References (32)

1. Royce ME, Baumgartner KB, Baumgartner R.N., et al. Factors influencing breast cancer prognosis: divergent patterns for Hispanic and non-Hispanic white women in New Mexico - The Health, Eating, Activity and Lifestyle (HEAL) Study. Breast Cancer Res Treat. 2004; 88(SUPPL. 1): S99.
2. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med. 2001; 7: 548-552.
3. Nathanson KN, Wooster R, Weber BL Breast cancer genetics: what we know and what we need. Nat Med. 2001; 7: 552-556.
4. Chhieng DC, Frost AR, Niwas S, et al. Intratumor heterogeneity of biomarker expression in breast carcinoma. Biotech Histochem. 2004; 79910: 25-36.
5. Beerman H, Smit VT, Kluin P.M., et al. Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast carcinoma. Cytometry. 1991; 12: 147-154.
6. Meyer JS, Wittliff JL Regional heterogeneity in breast carcinoma: thymidine labeling index, steroid hormone receptors, DNA ploidy. Int J Cancer. 1991; 47: 213-220.
7. Ferno M, Baldetorp B, Ewers S.B., et al. One or multiple samplings for flow cytometric DNA analyses in breast cancer-prognostic implications? Cytometry. 1992; 13: 241-249.
8. Borie N, Bertucci F, Groulet-Martinec A, et al. A gene expression profiling defines new molecular classes and predicts prognosis in breast cancer patients treated with adjuvant chemotherapy: development of a clinical tool to improve management of breast cancer. Breast Cancer Res Treat. 2004; 88(SUPPL. 1): S195.
9. Romain S, Chinot O, Guirou O., et al. Biological heterogeneity of ER-positive breast cancers in post-menopausal population. Int J Cancer. 1994; 59: 17-19.
10. Paradiso A, Mangia A, Barletta A., et al. Heterogeneity of intratumor proliferative activity in primary breast cancer: biological and clinical aspects. Eur J Cancer. 1995; 31A: 911-916.
11. Bergers E, Van Diest PJ, Baak JP Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J Clin Pathol. 1996; 49: 931-937.
12. Assailly J, Desgrippes A, Loridon-Rosa B, et al. Heterogeneity of DNA distribution in diploid cells: a new predictive discriminant factor for solid tumour behaviour. Anal Cell Pathol. 1999; 18: 103-108.
13. Visscher D, Dolan P, Ottseb S., et al. Geographic distribution of co-dominant DNA stemlines in breast carcinoma. Cytometry. 1995; 21: 14-17.
14. Pertschuk LP, Constantine AA, Feldman J.G., et al. Marked intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems. Breast J. 1999; 5: 369-374.
15. Glockner S, Buurman H, Kleeberger W., et al. Marked intratumoral heterogeneity of c-myc and cyclin-D1 but not of c-erbB2 amplification in breast cancer. Lab Invest. 2002; 82: 1419-1426.
16. Denk H. Immunohistologic heterogeneity of malignant tumors. Pathol Res Pract. 1988; 183: 693-697.
17. Veronese SM, Gambacorta M, Gottardi O., et al. Proliferation index as a prognostic marker in breast cancer. Cancer. 1993; 71: 3926-3931.
18. Hsu B, Marin MC, Brisbay S, et al. Expression of bcl-2 gene confers multidrug resistance to chemotherapy-induced cell death. Cancer Bull. 1994; 46: 125-129.
19. Chevillard S, Pouillart P, Beldjord C., et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer. 1996; 77: 292-300.
20. Symmans WF, Volm MD, Shapiro R.L., et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res. 2000; 6: 4610-4617.
21. Bloom HJG, Richardson WW Histologic grading and prognosis in breast carcinoma: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11: 359-377.
22. Portney LG, Watkins MP Foundations of Clinical Research. Applications to Practice. Third Edition. Chapter 26: Statistical Measures of Reliability. Pearson Education Inc, Upper Saddle River, NJ; 2009: 588-598.
23. Vance GH, Barry TS, Bloom K.J., et al. Genetic heterogeneity in her2 testing in breast cancer. Panel summary and guidelines. Arch Pathol Lab Med. 2009; 133: 611-613.
24. Siitonen SM, Isola JJ, Rantala I.S., et al. Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. Am J Clin Pathol. 1993; 99: 226-231.
25. Symmans WF, Liu J, Knowles D.M., et al. Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol. 1995; 26: 210-216.
26. Frierson HF Jr. Ploidy analysis and S-phase fraction determination by flow cytometry of invasive adenocarcinomas of the breast. Am J Surg Pathol. 1991; 15: 358-367.
27. Andersson J, Linderholm B, Bergh J., et al. Her-2/neu (C-erb-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol. 2004; 12: 14-20.
28. Cottu PH, Lae AM, Pierga J.Y., et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for management of advanced breast cancer. Ann Oncol. 2008; 19: 596-597.
29. Hanna W, Nofech-Mozes S, Kahn HJ Intratumoral heterogeneity of HER2/neu in breast cancer - a rare event. Breast J. 2007; 13: 122-129.
30. Moriki T, Tkahashi T, Ueta S., et al. Hormone receptor status and Her2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol. 2004; 30: 251-256.
31. Lacroix M, Toillon RA, Leclecrq G. Stable "portrait" of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer. 2004; 11: 497-522.
32. Mahler-Araujo B., Savage K, Parry S., et al. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol. 2008; 61: 615-620.